Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax: 2022-2025

Historic Long-Term Deferred Tax for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Sep 2025 value amounting to $25.0 million.

  • Centessa Pharmaceuticals' Long-Term Deferred Tax fell 7.51% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year decrease of 7.51%. This contributed to the annual value of $26.6 million for FY2024, which is 10.32% down from last year.
  • Centessa Pharmaceuticals' Long-Term Deferred Tax amounted to $25.0 million in Q3 2025, which was down 1.36% from $25.4 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $29.6 million during Q4 2023, with a 5-year trough of $3.5 million in Q4 2022.
  • Its 3-year average for Long-Term Deferred Tax is $27.4 million, with a median of $26.9 million in 2023.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first skyrocketed by 744.16% in 2023, then decreased by 11.27% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $3.5 million in 2022, then skyrocketed by 744.16% to $29.6 million in 2023, then fell by 10.32% to $26.6 million in 2024, then decreased by 7.51% to $25.0 million in 2025.
  • Its last three reported values are $25.0 million in Q3 2025, $25.4 million for Q2 2025, and $26.4 million during Q1 2025.